论文信息 - Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome. - 字舞流文

Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome.

T. Ørntoft | E. Steyerberg | N. Malats | M. Kogevinas | M. Márquez | A. Carrato | J. Lloreta | F. Real | Y. Allory | E. Zwarthoff | A. Sagrera | L. Dyrskjøt | M. Flández | E. Pau | M. Marqués | I. Lurkin | W. Beukers | T. Zuiverloon | Kirstin A. van der Keur | M. Vermeij | T. Orntoft | J. Lorente | A. V. van Tilborg | R. Masius | A. V. Tilborg | C. Abas | E. Carrillo-de Santa Pau | M. Flández | K. A. V. D. Keur | Willemien Beukers | Enrique Carrillo-de Santa Pau

[1] Gary L. Gallia,et al. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal , 2013, Proceedings of the National Academy of Sciences.

[2] D. Schadendorf,et al. TERT Promoter Mutations in Familial and Sporadic Melanoma , 2013, Science.

[3] P. Clark,et al. Management of superficial and muscle-invasive urothelial cancers of the bladder , 2013, Current opinion in oncology.

[4] K. Rudolph,et al. The Role of Telomeres in Stem Cells and Cancer , 2013, Cell.

[5] D. Gomez,et al. AZT as a telomerase inhibitor , 2012, Front. Oncol..

[6] A. Bossi. Re: Arnulf Stenzl, Nigel C. Cowan, Maria De Santis, et al. Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU Guidelines. Eur Urol 2011;59:1009-18. , 2011, European urology.

[7] H. Grossman,et al. Urine markers for detection and surveillance of non-muscle-invasive bladder cancer. , 2011, European urology.

[8] M. Babjuk,et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. , 2011, European urology.

[9] J. Witjes,et al. Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines. , 2011, European urology.

[10] T. H. van der Kwast,et al. FGFR3, HRAS, KRAS, NRAS and PIK3CA Mutations in Bladder Cancer and Their Potential as Biomarkers for Surveillance and Therapy , 2010, PloS one.

[11] Hester F. Lingsma,et al. Fibroblast Growth Factor Receptor 3 Mutation Analysis on Voided Urine for Surveillance of Patients with Low-Grade Non-Muscle–Invasive Bladder Cancer , 2010, Clinical Cancer Research.

[12] N. Malats,et al. Prospective study of FGFR3 mutations as a prognostic factor in nonmuscle invasive urothelial bladder carcinomas. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13] E. Zwarthoff,et al. A Simple and Fast Method for the Simultaneous Detection of Nine Fibroblast Growth Factor Receptor 3 Mutations in Bladder Cancer and Voided Urine , 2005, Clinical Cancer Research.

[14] O. Nanni,et al. Relevance of urine telomerase in the diagnosis of bladder cancer. , 2005, JAMA.

[15] N. Malats,et al. NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses , 2005, The Lancet.

[16] M. A. Goldman. The role of telomeres and telomerase in cancer. , 2003, Drug discovery today.

[17] C. Abbou,et al. Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors. , 2001, The American journal of pathology.

[18] D. Chopin,et al. Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas , 1999, Nature Genetics.

[19] W. Isaacs,et al. Molecular biology of bladder cancer. , 1992, Hematology/oncology clinics of North America.

[20] D. Schadendorf,et al. Highly Recurrent TERT Promoter Mutations in Human Melanoma , 2022 .